이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 백금 저항성 난소암에서 각 약물 단독 요법 또는 다른 화학 요법과 비교하여 Cediranib 및 Olaparib의 조합 테스트

2026년 9월 30일 업데이트: National Cancer Institute (NCI)

재발성 백금 저항성 또는 불응성 난소암, 나팔관암 또는 원발성 복막암(COCOS)이 있는 여성에서 세디라닙 또는 올라파립 단독 요법 또는 표준 치료 화학 요법과 비교한 세디라닙 및 올라파립의 병용에 대한 무작위 II/III상 연구

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVES:

I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by overall survival (OS) and PFS, as compared to physician's choice standard of care chemotherapy in women with recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by objective response rate (ORR: partial or complete response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess safety endpoints, as measured by frequency and severity of adverse events by Common Terminology Criteria for Adverse Events (CTCAE). (Phase II and Phase III) III. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by ORR as compared to physician's choice standard of care chemotherapy in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

OBJECTIVES WITH INTEGRATED BIOMARKERS:

I. To assess correlation of homologous recombination deficiency (HRD) status, as assessed via BROCA-HR assay with response, as measured by PFS and ORR. (Phase II) II. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase II) III. To evaluate quality of life data compliance, as measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI) for utilization and analysis in the Phase III study. (Phase II) IV. To assess correlation of HRD status, as assessed via BROCA-HR assay with response, as measured by OS, PFS and ORR. (Phase III) V. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase III) VI. To assess the effect on disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

EXPLORATORY OBJECTIVES:

I. To assess exploratory biomarkers of potential HRD, including genomic scarring, BRCA1 methylation, BRCA1 protein expression, and mutations in NHEJ, and other genes that might modify HRD. (Phase II and Phase III) II. To evaluate the prognostic and predictive role of angiogenic biomarkers, as assessed by the Duke plasma angiome. (Phase II and Phase III) III. To assess the effect on secondary measures of quality of life, as assessed by the treatment side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory neuropathy as measured by the FACT/GOG-Ntx-4, and health utility as measured by the EQ-5D, of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

OUTLINE:

PHASE II: Patients are randomized to 1 of 4 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel intravenously (IV) over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo computed tomography (CT) and magnetic resonance imaging (MRI) throughout the study. (12/05/2016)

ARM II (CEDIRANIB MALEATE AND OLAPARIB): Patients receive cediranib maleate orally (PO) once daily (QD) and olaparib PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

ARM III (CEDIRANIB): Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

ARM IV (OLAPARIB): Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).

PHASE III: Patients are randomized to 1 of 3 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)

ARM II (CEDIRANIB AND OLAPARIB): Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.

ARM III (SINGLE AGENT): Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for up to 3 years.

연구 유형

중재적

등록 (실제)

582

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 대한민국
      • Incheon, 대한민국, 405-760
        • Gachon University Gil Hospital
      • Seoul, 대한민국, 05505
        • Asan Medical Center
      • Seoul, 대한민국, 06273
        • Gangnam Severance Hospital
      • Seoul, 대한민국, 134-727
        • Kyung Hee University Hospital at Gangdong
      • Seoul, 대한민국, 139-706
        • Korea Cancer Center Hospital
    • Daegu
      • Dalseo-gu, Daegu, 대한민국, 42601
        • Keimyung University-Dongsan Medical Center
    • Kyeonggi-do
      • Seongnam, Kyeonggi-do, 대한민국, 463-707
        • Seoul National University Bundang Hospital
  • 미국
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • University of Alabama at Birmingham Cancer Center
    • Alaska
      • Anchorage, Alaska, 미국, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, 미국, 99508
        • Providence Alaska Medical Center
    • Arkansas
      • Little Rock, Arkansas, 미국, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Auburn, California, 미국, 95602
        • Sutter Auburn Faith Hospital
      • Berkeley, California, 미국, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Carmichael, California, 미국, 95608
        • Mercy San Juan Medical Center
      • Elk Grove, California, 미국, 95758
        • Mercy Cancer Center - Elk Grove
      • Greenbrae, California, 미국, 94904
        • Marin Cancer Care Inc
      • La Jolla, California, 미국, 92093
        • UC San Diego Moores Cancer Center
      • Mountain View, California, 미국, 94040
        • Palo Alto Medical Foundation-Camino Division
      • Mountain View, California, 미국, 94040
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • Oakland, California, 미국, 94611
        • Kaiser Permanente-Oakland
      • Palo Alto, California, 미국, 94301
        • Palo Alto Medical Foundation Health Care
      • Rocklin, California, 미국, 95765
        • Mercy Cancer Center - Rocklin
      • Roseville, California, 미국, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, 미국, 95816
        • Sutter Medical Center Sacramento
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
      • Sacramento, California, 미국, 95814
        • Kaiser Permanente Downtown Commons
      • Sacramento, California, 미국, 95825
        • Kaiser Permanente Sacramento Medical Center
      • Sacramento, California, 미국, 95816
        • Mercy Cancer Center - Sacramento
      • San Francisco, California, 미국, 94115
        • Kaiser Permanente-San Francisco
      • San Francisco, California, 미국, 94158
        • UCSF Medical Center-Mission Bay
      • San Francisco, California, 미국, 94115
        • California Pacific Medical Center-Pacific Campus
      • San Luis Obispo, California, 미국, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • Santa Clara, California, 미국, 95051
        • Kaiser Permanente Medical Center - Santa Clara
      • Santa Cruz, California, 미국, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Rosa, California, 미국, 95403
        • Sutter Pacific Medical Foundation
      • Sunnyvale, California, 미국, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Vallejo, California, 미국, 94589
        • Kaiser Permanente-Vallejo
      • Walnut Creek, California, 미국, 94596
        • Kaiser Permanente-Walnut Creek
      • Woodland, California, 미국, 95695
        • Woodland Memorial Hospital
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • UCHealth University of Colorado Hospital
      • Colorado Springs, Colorado, 미국, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, 미국, 80909
        • UCHealth Memorial Hospital Central
      • Denver, Colorado, 미국, 80205
        • Kaiser Permanente-Franklin
      • Denver, Colorado, 미국, 80220
        • Rocky Mountain Cancer Centers-Rose
      • Fort Collins, Colorado, 미국, 80524
        • Poudre Valley Hospital
      • Highlands Ranch, Colorado, 미국, 80129
        • UCHealth Highlands Ranch Hospital
      • Lafayette, Colorado, 미국, 80026
        • Kaiser Permanente-Rock Creek
      • Lone Tree, Colorado, 미국, 80124
        • Kaiser Permanente-Lone Tree
    • Connecticut
      • Danbury, Connecticut, 미국, 06810
        • Danbury Hospital
      • Fairfield, Connecticut, 미국, 06824
        • Smilow Cancer Hospital Care Center-Fairfield
      • Hartford, Connecticut, 미국, 06105
        • Smilow Cancer Hospital Care Center at Saint Francis
      • Hartford, Connecticut, 미국, 06102
        • Hartford Hospital
      • Middletown, Connecticut, 미국, 06457
        • Middlesex Hospital
      • New Britain, Connecticut, 미국, 06050
        • The Hospital of Central Connecticut
      • New Haven, Connecticut, 미국, 06520
        • Yale University
      • Norwalk, Connecticut, 미국, 06856
        • Norwalk Hospital
      • Trumbull, Connecticut, 미국, 06611
        • Smilow Cancer Hospital Care Center-Trumbull
    • Delaware
      • Newark, Delaware, 미국, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, 미국, 19713
        • Medical Oncology Hematology Consultants PA
      • Newark, Delaware, 미국, 19718
        • Christiana Care Health System-Christiana Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20016
        • Sibley Memorial Hospital
    • Florida
      • Gainesville, Florida, 미국, 32610
        • UF Health Cancer Institute - Gainesville
      • Miami Beach, Florida, 미국, 33140
        • Mount Sinai Medical Center
      • Orlando, Florida, 미국, 32806
        • Orlando Health Cancer Institute
      • Sarasota, Florida, 미국, 34239
        • Sarasota Memorial Hospital
    • Georgia
      • Atlanta, Georgia, 미국, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, 미국, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, 미국, 30309
        • Piedmont Hospital
      • Atlanta, Georgia, 미국, 30342
        • Northside Hospital
      • Augusta, Georgia, 미국, 30912
        • Augusta University Medical Center
      • Austell, Georgia, 미국, 30106
        • WellStar Cobb Hospital
      • Marietta, Georgia, 미국, 30060
        • Wellstar Kennestone Hospital
      • Marietta, Georgia, 미국, 30060
        • WellStar Health System Inc
      • Roswell, Georgia, 미국, 30076
        • WellStar North Fulton Hospital
      • Savannah, Georgia, 미국, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
      • Savannah, Georgia, 미국, 31404
        • Memorial Health University Medical Center
      • Smyrna, Georgia, 미국, 30080
        • WellStar Vinings Health Park
    • Hawaii
      • Honolulu, Hawaii, 미국, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, 미국, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, 미국, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, 미국, 83712
        • Saint Luke's Cancer Institute - Boise
      • Fruitland, Idaho, 미국, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, 미국, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, 미국, 83687
        • Saint Luke's Cancer Institute - Nampa
    • Illinois
      • Aurora, Illinois, 미국, 60504
        • Rush-Copley Medical Center
      • Bloomington, Illinois, 미국, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, 미국, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, 미국, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, 미국, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Chicago, Illinois, 미국, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, 미국, 60657
        • UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital
      • Chicago, Illinois, 미국, 60612
        • Rush MD Anderson Cancer Center
      • Decatur, Illinois, 미국, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, 미국, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Effingham, Illinois, 미국, 62401
        • Crossroads Cancer Center
      • Eureka, Illinois, 미국, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, 미국, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, 미국, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, 미국, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, 미국, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Highland Park, Illinois, 미국, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Hinsdale, Illinois, 미국, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Kewanee, Illinois, 미국, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, 미국, 61455
        • Illinois CancerCare-Macomb
      • O'Fallon, Illinois, 미국, 62269
        • Cancer Care Center of O'Fallon
      • Ottawa, Illinois, 미국, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, 미국, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, 미국, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, 미국, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, 미국, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, 미국, 62702
        • Springfield Clinic
      • Springfield, Illinois, 미국, 62781
        • Springfield Memorial Hospital
      • Warrenville, Illinois, 미국, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Zion, Illinois, 미국, 60099
        • Midwestern Regional Medical Center
    • Indiana
      • Fort Wayne, Indiana, 미국, 46845
        • Parkview Regional Medical Center
      • Indianapolis, Indiana, 미국, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, 미국, 46260
        • Ascension Saint Vincent Indianapolis Hospital
      • Richmond, Indiana, 미국, 47374
        • Reid Health
      • South Bend, Indiana, 미국, 46601
        • Memorial Hospital of South Bend
    • Iowa
      • Clive, Iowa, 미국, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, 미국, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, 미국, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Iowa City, Iowa, 미국, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Sioux City, Iowa, 미국, 51101
        • Siouxland Regional Cancer Center
      • West Des Moines, Iowa, 미국, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Wichita, Kansas, 미국, 67214
        • Ascension Via Christi Hospitals Wichita
      • Wichita, Kansas, 미국, 67208
        • Associates In Womens Health
    • Kentucky
      • Edgewood, Kentucky, 미국, 41017
        • Saint Elizabeth Healthcare Edgewood
      • Lexington, Kentucky, 미국, 40536
        • University of Kentucky/Markey Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, 미국, 70809
        • Mary Bird Perkins Cancer Center
      • Baton Rouge, Louisiana, 미국, 70809
        • Hematology/Oncology Clinic PLLC
      • Baton Rouge, Louisiana, 미국, 70817
        • Woman's Hospital
      • Covington, Louisiana, 미국, 70433
        • Women's Cancer Care-Covington
      • New Orleans, Louisiana, 미국, 70121
        • Ochsner Medical Center Jefferson
    • Maine
      • Bangor, Maine, 미국, 04401
        • Eastern Maine Medical Center
      • Brewer, Maine, 미국, 04412
        • Lafayette Family Cancer Center-EMMC
      • Scarborough, Maine, 미국, 04074
        • MaineHealth Maine Medical Center- Scarborough
    • Maryland
      • Baltimore, Maryland, 미국, 21237
        • MedStar Franklin Square Medical Center/Weinberg Cancer Institute
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, 미국, 21204
        • Greater Baltimore Medical Center
      • Bel Air, Maryland, 미국, 21014
        • UM Upper Chesapeake Medical Center
      • Bethesda, Maryland, 미국, 20892
        • National Institutes of Health Clinical Center
      • Ocean Pines, Maryland, 미국, 21811
        • TidalHealth Richard A Henson Cancer Institute
      • Salisbury, Maryland, 미국, 21801
        • TidalHealth Peninsula Regional
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, 미국, 02115
        • Brigham and Women's Hospital
      • Worcester, Massachusetts, 미국, 01605
        • UMass Memorial Medical Center - Memorial Division
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan Rogel Cancer Center
      • Ann Arbor, Michigan, 미국, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brownstown, Michigan, 미국, 48183
        • Henry Ford Cancer Institute-Downriver
      • Clinton Township, Michigan, 미국, 48038
        • Henry Ford Macomb Hospital-Clinton Township
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Hospital
      • Detroit, Michigan, 미국, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Escanaba, Michigan, 미국, 49829
        • OSF Saint Francis Hospital and Medical Group
      • Farmington Hills, Michigan, 미국, 48334
        • Weisberg Cancer Treatment Center
      • Grand Rapids, Michigan, 미국, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo, Michigan, 미국, 49007
        • West Michigan Cancer Center
      • Lansing, Michigan, 미국, 48912
        • University of Michigan Health - Sparrow Lansing
      • Pontiac, Michigan, 미국, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Traverse City, Michigan, 미국, 49684
        • Munson Medical Center
      • West Bloomfield, Michigan, 미국, 48322
        • Henry Ford West Bloomfield Hospital
    • Minnesota
      • Bemidji, Minnesota, 미국, 56601
        • Sanford Joe Lueken Cancer Center
      • Burnsville, Minnesota, 미국, 55337
        • Fairview Ridges Hospital
      • Coon Rapids, Minnesota, 미국, 55433
        • Mercy Hospital
      • Edina, Minnesota, 미국, 55435
        • Fairview Southdale Hospital
      • Mankato, Minnesota, 미국, 56001
        • Mayo Clinic Health Systems-Mankato
      • Maple Grove, Minnesota, 미국, 55369
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, 미국, 55109
        • Saint John's Hospital - Healtheast
      • Minneapolis, Minnesota, 미국, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, 미국, 55455
        • University of Minnesota/Masonic Cancer Center
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic in Rochester
      • Saint Louis Park, Minnesota, 미국, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, 미국, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, 미국, 55102
        • United Hospital
      • Shakopee, Minnesota, 미국, 55379
        • Saint Francis Regional Medical Center
      • Woodbury, Minnesota, 미국, 55125
        • Minnesota Oncology Hematology PA-Woodbury
    • Mississippi
      • Jackson, Mississippi, 미국, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Cape Girardeau, Missouri, 미국, 63703
        • Saint Francis Medical Center
      • Columbia, Missouri, 미국, 65212
        • MU Health - University Hospital/Ellis Fischel Cancer Center
      • Joplin, Missouri, 미국, 64804
        • Mercy Hospital Joplin
      • Springfield, Missouri, 미국, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, 미국, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, 미국, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
    • Montana
      • Billings, Montana, 미국, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, 미국, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, 미국, 59405
        • Benefis Sletten Cancer Institute
    • Nebraska
      • Grand Island, Nebraska, 미국, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, 미국, 68847
        • CHI Health Good Samaritan
      • Omaha, Nebraska, 미국, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, 미국, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, 미국, 68130
        • Alegent Health Lakeside Hospital
    • Nevada
      • Las Vegas, Nevada, 미국, 89106
        • Women's Cancer Center of Nevada
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
      • Nashua, New Hampshire, 미국, 03063
        • Dartmouth Cancer Center - Nashua
    • New Jersey
      • Camden, New Jersey, 미국, 08103
        • Cooper Hospital University Medical Center
      • Hackensack, New Jersey, 미국, 07601
        • Hackensack University Medical Center
      • Hamilton, New Jersey, 미국, 08690
        • The Cancer Institute of New Jersey Hamilton
      • Morristown, New Jersey, 미국, 07960
        • Morristown Medical Center
      • Neptune City, New Jersey, 미국, 07753
        • Jersey Shore Medical Center
      • New Brunswick, New Jersey, 미국, 08903
        • Rutgers Cancer Institute of New Jersey
      • Somerville, New Jersey, 미국, 08876
        • Robert Wood Johnson University Hospital Somerset
      • Summit, New Jersey, 미국, 07902
        • Overlook Hospital
      • Voorhees Township, New Jersey, 미국, 08043
        • MD Anderson Cancer Center at Cooper-Voorhees
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87106
        • Southwest Gynecologic Oncology Associates Inc
      • Albuquerque, New Mexico, 미국, 87106
        • University of New Mexico Cancer Center
      • Las Cruces, New Mexico, 미국, 88011
        • Memorial Medical Center-Las Cruces
    • New York
      • Albany, New York, 미국, 12208
        • Women's Cancer Care Associates LLC
      • Brooklyn, New York, 미국, 11203
        • State University of New York Downstate Medical Center
      • Buffalo, New York, 미국, 14263
        • Roswell Park Cancer Institute
      • New York, New York, 미국, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester, New York, 미국, 14642
        • University of Rochester
      • Stony Brook, New York, 미국, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, 미국, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, 미국, 10461
        • Montefiore Medical Center-Einstein Campus
      • White Plains, New York, 미국, 10601
        • Dickstein Cancer Treatment Center
    • North Carolina
      • Asheville, North Carolina, 미국, 28803
        • AdventHealth Infusion Center Asheville
      • Chapel Hill, North Carolina, 미국, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Clyde, North Carolina, 미국, 28721
        • AdventHealth Infusion Center Haywood
      • Durham, North Carolina, 미국, 27710
        • Duke University Medical Center
      • Goldsboro, North Carolina, 미국, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Hendersonville, North Carolina, 미국, 28791
        • Margaret R Pardee Memorial Hospital
      • Hendersonville, North Carolina, 미국, 28792
        • AdventHealth Hendersonville
      • Jacksonville, North Carolina, 미국, 28546
        • Southeastern Medical Oncology Center-Jacksonville
      • Pinehurst, North Carolina, 미국, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
      • Raleigh, North Carolina, 미국, 27609
        • Duke Cancer Center Raleigh
      • Wilmington, North Carolina, 미국, 28401
        • Novant Health New Hanover Regional Medical Center
      • Winston-Salem, North Carolina, 미국, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Broadway Medical Center
    • Ohio
      • Akron, Ohio, 미국, 44307
        • Cleveland Clinic Akron General
      • Canton, Ohio, 미국, 44710
        • Aultman Health Foundation
      • Centerville, Ohio, 미국, 45459
        • Miami Valley Hospital South
      • Cincinnati, Ohio, 미국, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cincinnati, Ohio, 미국, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, 미국, 45247
        • TriHealth Cancer Institute-Westside
      • Cleveland, Ohio, 미국, 44109
        • MetroHealth Medical Center
      • Cleveland, Ohio, 미국, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, 미국, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, 미국, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, 미국, 43219
        • The Mark H Zangmeister Center
      • Dayton, Ohio, 미국, 45405
        • Grandview Hospital
      • Findlay, Ohio, 미국, 45840
        • Orion Cancer Care
      • Mayfield Heights, Ohio, 미국, 44124
        • Hillcrest Hospital Cancer Center
      • Sylvania, Ohio, 미국, 43560
        • ProMedica Flower Hospital
      • Toledo, Ohio, 미국, 43606
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
      • West Chester, Ohio, 미국, 45069
        • University of Cincinnati Cancer Center-West Chester
      • Wright-Patterson Air Force Base, Ohio, 미국, 45433
        • Wright-Patterson Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, 미국, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
      • Tulsa, Oklahoma, 미국, 74133
        • Cancer Treatment Centers of America
    • Oregon
      • Bend, Oregon, 미국, 97701
        • Saint Charles Health System
      • Gresham, Oregon, 미국, 97030
        • Legacy Mount Hood Medical Center
      • Portland, Oregon, 미국, 97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Tualatin, Oregon, 미국, 97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Abington, Pennsylvania, 미국, 19001
        • Jefferson Abington Hospital
      • Bethlehem, Pennsylvania, 미국, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Bryn Mawr, Pennsylvania, 미국, 19010
        • Bryn Mawr Hospital
      • Danville, Pennsylvania, 미국, 17822
        • Geisinger Medical Center
      • Ephrata, Pennsylvania, 미국, 17522
        • Ephrata Cancer Center
      • Ephrata, Pennsylvania, 미국, 17522
        • Ephrata Community Hospital
      • Gettysburg, Pennsylvania, 미국, 17325
        • Adams Cancer Center
      • Hanover, Pennsylvania, 미국, 17331
        • WellSpan Medical Oncology and Hematology
      • Harrisburg, Pennsylvania, 미국, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Lebanon, Pennsylvania, 미국, 17042
        • Sechler Family Cancer Center
      • Lewisburg, Pennsylvania, 미국, 17837
        • Geisinger Medical Oncology-Lewisburg
      • Paoli, Pennsylvania, 미국, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, 미국, 19104
        • University of Pennsylvania/Abramson Cancer Center
      • Pittsburgh, Pennsylvania, 미국, 15224
        • West Penn Hospital
      • Sayre, Pennsylvania, 미국, 18840
        • Guthrie Medical Group PC-Robert Packer Hospital
      • West Reading, Pennsylvania, 미국, 19611
        • Reading Hospital
      • Wexford, Pennsylvania, 미국, 15090
        • Wexford Health and Wellness Pavilion
      • Williamsport, Pennsylvania, 미국, 17701
        • UPMC Susquehanna
      • Willow Grove, Pennsylvania, 미국, 19090
        • Asplundh Cancer Pavilion
      • Wynnewood, Pennsylvania, 미국, 19096
        • Lankenau Medical Center
      • York, Pennsylvania, 미국, 17403
        • WellSpan Health-York Hospital
    • Rhode Island
      • Providence, Rhode Island, 미국, 02905
        • Women and Infants Hospital
    • South Carolina
      • Anderson, South Carolina, 미국, 29621
        • AnMed Health Cancer Center
      • Gaffney, South Carolina, 미국, 29341
        • Gibbs Cancer Center-Gaffney
      • Greenville, South Carolina, 미국, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, 미국, 29601
        • Saint Francis Hospital
      • Greer, South Carolina, 미국, 29651
        • Gibbs Cancer Center-Pelham
      • Hilton Head Island, South Carolina, 미국, 29926-3827
        • South Carolina Cancer Specialists PC
      • Spartanburg, South Carolina, 미국, 29303
        • Spartanburg Medical Center
      • Union, South Carolina, 미국, 29379
        • SMC Center for Hematology Oncology Union
    • South Dakota
      • Rapid City, South Dakota, 미국, 57701
        • Rapid City Regional Hospital
      • Sioux Falls, South Dakota, 미국, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, 미국, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, 미국, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Kingsport, Tennessee, 미국, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, 미국, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Knoxville, Tennessee, 미국, 37916
        • Covenant Health Cancer Centers
      • Knoxville, Tennessee, 미국, 37932
        • Covenant Health Cancer Centers - West
      • Nashville, Tennessee, 미국, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Texas
      • Dallas, Texas, 미국, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, 미국, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Houston, Texas, 미국, 77030
        • Houston Methodist Hospital
      • Houston, Texas, 미국, 77070
        • Methodist Willowbrook Hospital
      • Sugar Land, Texas, 미국, 77479
        • Houston Methodist Sugar Land Hospital
    • Utah
      • Murray, Utah, 미국, 84107
        • Intermountain Medical Center
      • Salt Lake City, Utah, 미국, 84112
        • Huntsman Cancer Institute/University of Utah
      • Salt Lake City, Utah, 미국, 84106
        • Utah Cancer Specialists-Salt Lake City
      • South Jordan, Utah, 미국, 84009
        • South Jordan Health Center
      • St. George, Utah, 미국, 84770
        • Saint George Regional Medical Center
    • Vermont
      • Berlin Corners, Vermont, 미국, 05602
        • Central Vermont Medical Center/National Life Cancer Treatment
      • Burlington, Vermont, 미국, 05401
        • University of Vermont Medical Center
      • Burlington, Vermont, 미국, 05405
        • University of Vermont and State Agricultural College
    • Virginia
      • Charlottesville, Virginia, 미국, 22908
        • University of Virginia Cancer Center
      • Richmond, Virginia, 미국, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, 미국, 23298
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Bellingham, Washington, 미국, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Edmonds, Washington, 미국, 98026
        • Swedish Cancer Institute-Edmonds
      • Kennewick, Washington, 미국, 99336
        • Kadlec Clinic Hematology and Oncology
      • Mount Vernon, Washington, 미국, 98274
        • Skagit Valley Hospital
      • Mount Vernon, Washington, 미국, 98274
        • Skagit Regional Health Cancer Care Center
      • Seattle, Washington, 미국, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, 미국, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, 미국, 98133
        • University of Washington Medical Center - Northwest
      • Seattle, Washington, 미국, 98133
        • Women's Cancer Center of Seattle
      • Vancouver, Washington, 미국, 98686
        • Legacy Salmon Creek Hospital
      • Wenatchee, Washington, 미국, 98801
        • Wenatchee Valley Hospital and Clinics
    • West Virginia
      • Charleston, West Virginia, 미국, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
      • Huntington, West Virginia, 미국, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, 미국, 26506
        • West Virginia University Healthcare
      • Morgantown, West Virginia, 미국, 26505
        • Monongalia Hospital
    • Wisconsin
      • Appleton, Wisconsin, 미국, 54915
        • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
      • Burlington, Wisconsin, 미국, 53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Chippewa Falls, Wisconsin, 미국, 54729
        • Marshfield Clinic-Chippewa Center
      • Eau Claire, Wisconsin, 미국, 54701
        • Marshfield Clinic Cancer Center at Sacred Heart
      • Fond du Lac, Wisconsin, 미국, 54937
        • Aurora Health Center-Fond du Lac
      • Germantown, Wisconsin, 미국, 53022
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, 미국, 53024
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, 미국, 54311
        • Aurora BayCare Medical Center
      • Green Bay, Wisconsin, 미국, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, 미국, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • Kenosha, Wisconsin, 미국, 53142
        • Aurora Cancer Care-Kenosha South
      • La Crosse, Wisconsin, 미국, 54601
        • Gundersen Lutheran Medical Center
      • Ladysmith, Wisconsin, 미국, 54848
        • Marshfield Medical Center - Ladysmith
      • Madison, Wisconsin, 미국, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Marinette, Wisconsin, 미국, 54143
        • Aurora Bay Area Medical Group-Marinette
      • Marinette, Wisconsin, 미국, 54143
        • Saint Vincent Hospital Cancer Center at Marinette
      • Marshfield, Wisconsin, 미국, 54449
        • Marshfield Medical Center-Marshfield
      • Mequon, Wisconsin, 미국, 53097
        • Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, 미국, 53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, 미국, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, 미국, 53233
        • Aurora Sinai Medical Center
      • Milwaukee, Wisconsin, 미국, 53211
        • Ascension Columbia Saint Mary's Hospital-Milwaukee Campus
      • Minocqua, Wisconsin, 미국, 54548
        • Marshfield Medical Center - Minocqua
      • Mukwonago, Wisconsin, 미국, 53149
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, 미국, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oconto Falls, Wisconsin, 미국, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Oshkosh, Wisconsin, 미국, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Oshkosh, Wisconsin, 미국, 54904
        • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
      • Racine, Wisconsin, 미국, 53406
        • Aurora Cancer Care-Racine
      • Rice Lake, Wisconsin, 미국, 54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, 미국, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Stevens Point, Wisconsin, 미국, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Stevens Point, Wisconsin, 미국, 54481
        • Aspirus Cancer Care - Stevens Point
      • Sturgeon Bay, Wisconsin, 미국, 54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Summit, Wisconsin, 미국, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, 미국, 54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Waukesha, Wisconsin, 미국, 53188
        • UW Cancer Center at ProHealth Care
      • Waukesha, Wisconsin, 미국, 53188
        • ProHealth Waukesha Memorial Hospital
      • Wausau, Wisconsin, 미국, 54401
        • Marshfield Clinic-Wausau Center
      • Wauwatosa, Wisconsin, 미국, 53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, 미국, 53227
        • Aurora West Allis Medical Center
      • Weston, Wisconsin, 미국, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, 미국, 54494
        • Marshfield Clinic - Wisconsin Rapids Center
  • 일본
      • Osaka, 일본, 589 8511
        • Kindai University
      • Saitama, 일본, 350-1298
        • Saitama Medical University International Medical Center
      • Tokyo, 일본, 104 0045
        • National Cancer Center Hospital
    • Ehime
      • Tōon, Ehime, 일본, 791-0295
        • Ehime University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, 일본, 060-8648
        • Hokkaido University Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, 일본, 890-8760
        • Kagoshima City Hospital
    • Tokyo
      • Koto-ku, Tokyo, 일본, 135-8550
        • The Cancer Institute Hospital Of JFCR
  • 캐나다
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 5G2
        • Arthur J E Child Comprehensive Cancer Centre
      • Edmonton, Alberta, 캐나다, T6G 1Z2
        • Cross Cancer Institute
    • Ontario
      • Barrie, Ontario, 캐나다, L4M 6M2
        • Royal Victoria Regional Health Centre
      • Hamilton, Ontario, 캐나다, L8V 5C2
        • Juravinski Cancer Centre at Hamilton Health Sciences
      • Kingston, Ontario, 캐나다, K7L 2V7
        • Kingston Health Sciences Centre
      • London, Ontario, 캐나다, N6A 4L6
        • London Regional Cancer Program
      • Sault Ste. Marie, Ontario, 캐나다, P6B 0A8
        • Algoma District Cancer Program Sault Area Hospital
      • Toronto, Ontario, 캐나다, M5G 2M9
        • University Health Network-Princess Margaret Hospital
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Odette Cancer Centre- Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, 캐나다, H3T 1E2
        • Jewish General Hospital
      • Montreal, Quebec, 캐나다, H2X 3E4
        • CHUM - Centre Hospitalier de l'Universite de Montreal
      • Montreal, Quebec, 캐나다, H1T 2M4
        • CIUSSSEMTL-Hopital Maisonneuve-Rosemont
      • Québec, Quebec, 캐나다, G1R 2J6
        • CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
  • 푸에르토 리코
      • San Juan, 푸에르토 리코, 00927
        • Centro Comprensivo de Cancer de UPR

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings; both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory

    • Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing will be accepted; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germ line deleterious BRCA 1 or BRCA 2 mutation or BRCA rearrangement is required (12/05/2016); a copy of Myriad or other BRCA mutational analysis (positive or variants of unknown significance [VUS] or negative) reports will be requested but not required for study enrollment

  • Patients should have recurrent platinum-resistant or- refractory disease - defined as disease that has progressed by imaging while receiving platinum or had recurrence within 6 months of the last receipt of platinum-based chemotherapy; rising CA125 only is not considered as platinum-resistant or refractory disease (12/05/2016)

  • Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is not available tumor sample from fresh biopsy is acceptable (12/05/2016)

  • Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN])

  • No more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limit (12/05/2016)

  • Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed

  • Patients may not have previously received a PARP-inhibitor

  • Patient must have provided study specific informed consent prior to study entry

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2

  • Absolute neutrophil count >= 1,500/mcL (12/05/2016)

  • Platelets >= 100,000/mcL (12/05/2016)

  • Hemoglobin >= 10 g/dL (12/05/2016)

  • Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional limits (12/05/2016)

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN; if intrahepatic liver metastases are present, AST and ALT must be =< 5 times institutional ULN (12/05/2016)

  • Creatinine =< 1.5 x the institutional ULN (12/05/2016)

  • Urine protein: creatinine ratio urine protein creatinine (UPC) of =< 1 OR less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a 24-hour urine collection demonstrating protein of =< 500 mg over 24 hours (12/05/2016)

  • Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study chair.

  • Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib arms (12/05/2016)

  • Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid-stimulating hormone (TSH) within normal limits (12/05/2016)

  • Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib

  • Age >= 18 years

  • Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

  • Olaparib adversely affects embryofetal survival and development in the rat; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after the last dose of olaparib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions (12/05/2016)

  • Any other investigational agents within the past 4 weeks

  • Prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed

  • Prior use of PARP-inhibitors

  • CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease

  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib

  • Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs

  • History of intra-abdominal abscess within the past 3 months

  • History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula (12/05/2016)

  • Dependency on IV hydration or total parenteral nutrition (TPN)

  • Any concomitant or prior invasive malignancies with the following curatively treated exceptions:

    • Treated limited stage basal cell or squamous cell carcinoma of the skin
    • Carcinoma in situ of the breast or cervix
    • Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions (12/05/2016)
    • Prior cancer treated with a curative intent with no evidence of recurrent disease 5 years following diagnosis and judged by the investigator to be at low risk of recurrence

  • Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug

  • Patients with any of the following:

    • History of myocardial infarction within six months
    • Unstable angina
    • Resting electrocardiogram (ECG) with clinically significant abnormal findings
    • New York Heart Association functional classification of III or IV

  • If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines

    • Patients with the following risk factors should have a baseline cardiac function assessment:

      • Prior treatment with anthracyclines
      • Prior treatment with trastuzumab
      • Prior central thoracic radiation therapy (RT), including RT to the heart
      • History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
      • Prior history of impaired cardiac function

  • History of stroke or transient ischemic attack within six months

  • Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)

  • Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted

  • Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated

    • No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)

  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements (12/05/2016)

  • Known human immunodeficiency virus (HIV)-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy

  • Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible

    • Strong inhibitors and inducers of UGT/PgP should be used with caution (12/05/2016)

  • Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Phase II Arm I (reference regimen)

Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
의약품: Paclitaxel

Given IV

다른 이름들:
  • 탁솔
  • 안자탁스
  • 아소탁스
  • 브리스타솔
  • 프락셀
  • 탁솔 콘첸트라트
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

다른 이름들:
  • ATI-0918
  • Caelyx
  • 독실
  • 독실렌
  • 독소루비신 HCl 리포좀
  • 두오메이수
  • 에바셋
  • 리포독스
  • 리포솜 아드리아마이신
  • 리포솜 캡슐화된 독소루비신
  • 페길화된 독소루비신 HCl 리포좀
  • S-리포좀 독소루비신
  • 스텔스 리포솜 독소루비신
  • TLC D-99
  • Dox-SL
  • 독소루비신 HCl 리포솜
  • 독소루비신 염산염 리포솜
  • 리포독스 50
  • 리포솜 독소루비신 염산염
  • 페길화된 리포솜 독소루비신
  • 리포솜 독소루비신
의약품: Topotecan

Given IV

다른 이름들:
  • 히캄파민
  • 토포테칸 락톤
의약품: Topotecan Hydrochloride

Given IV

다른 이름들:
  • 하이캄틴
  • 히캄파민
  • SKF S-104864-A
  • 토포테칸 HCl
  • 토포테칸 염산염(경구)
  • 포탁타솔
  • 에보토핀
  • 토포텍
  • 노기테칸 염산염
  • SKF S 104864 A
  • SKF S104864A
실험적: Phase II Arm II (cediranib maleate, olaparib)

Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Cediranib Maleate

Given PO

다른 이름들:
  • AZD2171
  • AZD2171 말레이트
  • 레센틴
의약품: Olaparib

Given PO

다른 이름들:
  • 린파자
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP 억제제 AZD2281
  • KU0059436
  • 올라닙
  • 올라파릭스
  • 쿠 0059436
의약품: Cediranib

Given PO

다른 이름들:
  • AZD2171
  • AZ-D2171
  • AZD 2171
실험적: Phase II Arm III (cediranib maleate)

Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Cediranib Maleate

Given PO

다른 이름들:
  • AZD2171
  • AZD2171 말레이트
  • 레센틴
의약품: Cediranib

Given PO

다른 이름들:
  • AZD2171
  • AZ-D2171
  • AZD 2171
실험적: Phase II Arm IV (olaparib)

Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Olaparib

Given PO

다른 이름들:
  • 린파자
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP 억제제 AZD2281
  • KU0059436
  • 올라닙
  • 올라파릭스
  • 쿠 0059436
활성 비교기: Phase III Arm I (reference regimen)

Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
의약품: Paclitaxel

Given IV

다른 이름들:
  • 탁솔
  • 안자탁스
  • 아소탁스
  • 브리스타솔
  • 프락셀
  • 탁솔 콘첸트라트
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

다른 이름들:
  • ATI-0918
  • Caelyx
  • 독실
  • 독실렌
  • 독소루비신 HCl 리포좀
  • 두오메이수
  • 에바셋
  • 리포독스
  • 리포솜 아드리아마이신
  • 리포솜 캡슐화된 독소루비신
  • 페길화된 독소루비신 HCl 리포좀
  • S-리포좀 독소루비신
  • 스텔스 리포솜 독소루비신
  • TLC D-99
  • Dox-SL
  • 독소루비신 HCl 리포솜
  • 독소루비신 염산염 리포솜
  • 리포독스 50
  • 리포솜 독소루비신 염산염
  • 페길화된 리포솜 독소루비신
  • 리포솜 독소루비신
의약품: Topotecan

Given IV

다른 이름들:
  • 히캄파민
  • 토포테칸 락톤
의약품: Topotecan Hydrochloride

Given IV

다른 이름들:
  • 하이캄틴
  • 히캄파민
  • SKF S-104864-A
  • 토포테칸 HCl
  • 토포테칸 염산염(경구)
  • 포탁타솔
  • 에보토핀
  • 토포텍
  • 노기테칸 염산염
  • SKF S 104864 A
  • SKF S104864A
실험적: Phase III Arm II (cediranib maleate, olaparib)

Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Cediranib Maleate

Given PO

다른 이름들:
  • AZD2171
  • AZD2171 말레이트
  • 레센틴
의약품: Olaparib

Given PO

다른 이름들:
  • 린파자
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP 억제제 AZD2281
  • KU0059436
  • 올라닙
  • 올라파릭스
  • 쿠 0059436
의약품: Cediranib

Given PO

다른 이름들:
  • AZD2171
  • AZ-D2171
  • AZD 2171
실험적: Phase III Arm III (single-agent cediranib maleate)

Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
절차: Computed Tomography

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
절차: Magnetic Resonance Imaging

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI
다른: Questionnaire Administration

Ancillary studies

의약품: Cediranib Maleate

Given PO

다른 이름들:
  • AZD2171
  • AZD2171 말레이트
  • 레센틴
의약품: Cediranib

Given PO

다른 이름들:
  • AZD2171
  • AZ-D2171
  • AZD 2171

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival (PFS) (Phase II Only)
기간: The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.

Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments.

Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.
Progression-free Survival (PFS) (Phase III Only)
기간: The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.

Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments.

Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.
Overall Survival (OS) (Phase III Only)
기간: Time from study enrollment to death due to any cause, assessed up to 5 years

Overall survival will be evaluated. To allow for better understanding of time to subsequent therapy and OS, patients on experimental study drug(s) or standard chemotherapy arm will be followed after progression, with data capture to include the date of initiation of the subsequent therapy, detailed information on the type of subsequent therapy received, and time to progression on the subsequent therapy.
Time from study enrollment to death due to any cause, assessed up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (Complete Response and Partial Response) (Phase II Only)
기간: Up to 5 years

The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria.

A Complete response (CR) is defined as the complete disappearance of all target lesions, while a Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters of target lesions compared to the baseline measurement; essentially, the tumor shrinks significantly but does not completely disappear. Overall response (OR) = CR + PR.
Up to 5 years
Objective Response Rate (Complete Response and Partial Response for Phase III Only)
기간: Up to 5 years

The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria.

A Complete response (CR) is defined as the complete disappearance of all target lesions, while a Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters of target lesions compared to the baseline measurement; essentially, the tumor shrinks significantly but does not completely disappear. Overall response (OR) = CR + PR.
Up to 5 years
Incidence of Grade 3 (or Higher) Adverse Events
기간: Up to 5 years

Adverse events will be categorized by CTCAE V4.0. This outcome will report the count of participants who experienced a grade 3 (or higher) adverse event.
Up to 5 years

기타 결과 측정

결과 측정
측정값 설명
기간
Patient-reported Scores of Disease-related Symptoms
기간: Up to 5 years

Measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI-18).
Up to 5 years
Gene Mutations Assessed BROCA-HR
기간: Up to 5 years

A single proportional hazards model will be used to estimate the treatment hazard ratios (and variances) for each of the experimental treatments selected for phase III evaluation relative to the reference treatment (chemotherapy) group. The model will include adjustments for prior platinum-free interval, prior bevacizumab treatment, age at study enrollment, randomly assigned study treatment and BROCA-HR status. The estimated hazard ratio(s) for BROCA-HR and the corresponding confidence intervals will be depicted with a forest plot, and assessed for qualitative interaction(s).
Up to 5 years
Change in Circulating Endothelial Cell Levels
기간: Baseline up to 5 years

A proportional hazards model will be used to assess a linear association between the change in circulating endothelial cell values and the log relative hazard of death within each treatment group. Sensitivity analyses will include known prognostic factors in the model. A plot of the martingale residuals or estimated relative hazards by change in circulating endothelial cell quintiles will be used to qualitatively assess the assumption of a linear relationship between the change in circulating endothelial cell values and the log relative hazard.
Baseline up to 5 years
Biomarkers in Plasma Angiome
기간: Up to 5 years

A proportional hazards model will be used to assess whether the pretreatment values of any of these analytes have a prognostic association with overall survival. The model will include clinical covariates: age, performance status, and the randomly assigned study treatment. Proportional hazards models will be used to assess the relationship between patients' analyte values and log hazard. A proportional hazards model will be used to assess the potential predictive associations between analytes, treatment and survival.
Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

National Cancer Institute (NCI)

협력자

NRG Oncology
Canadian Cancer Trials Group

수사관

  • 수석 연구원: Jung-min Lee, NRG Oncology

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2016년 5월 3일

기본 완료 (실제)

2023년 6월 12일

연구 완료 (추정된)

2027년 3월 4일

연구 등록 날짜

최초 제출

2015년 7월 17일

QC 기준을 충족하는 최초 제출

2015년 7월 17일

처음 게시됨 (추정된)

2015년 7월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NCI-2015-00651
  • U10CA180868 (미국 NIH 보조금/계약)
  • NCI-2015-00651 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • NRG-GY005 (기타 식별자: CTEP)
  • s16-01681
  • NRG-GY005
  • NRG-GY005 (기타 식별자: NRG Oncology)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다